Copy Link Print Information

p38 MAPK-IN-1

15 Cited Publications
Avis client

Based on 15 publication(s) in Google Scholar

p38 MAPK-IN-1 (Compound 4) is a novel potent and selective inhibitor of p38 MAPK with IC50 of 68 nM. p38 MAPK-IN-1 shows sustained levels, low clearance and good bioavailability.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

  • Pureté: 99.71%
  • CAS No.: 1006378-90-0
  • Formule: C21H15F2N2O
  • Masse moléculaire:349.35
  • Stockage:
    Powder   -20°C, 3 years , 4°C, 2 years ; In solvent   -80°C, 2 years , -20°C, 1 year
  • p38 MAPK-IN-1 Chemical Structure
    p38 MAPK-IN-1 Chemical Structure
  • Experimental Validation Results for p38 MAPK-IN-1
  • Experimental Validation Results for p38 MAPK-IN-1
  • Experimental Validation Results for p38 MAPK-IN-1
  • Experimental Validation Results for p38 MAPK-IN-1
  • Experimental Validation Results for p38 MAPK-IN-1
  • Experimental Validation Results for p38 MAPK-IN-1
  • Experimental Validation Results for p38 MAPK-IN-1
  • Experimental Validation Results for p38 MAPK-IN-1
  • Experimental Validation Results for p38 MAPK-IN-1
  • Experimental Validation Results for p38 MAPK-IN-1
CAS No.: 1006378-90-0
Size
Prix
Stock
Quantité
Amount: USD 0.00
Please select quantity
or
or

* Veuillez sélectionner la quantité avant d'ajouter des articles.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Trouvez votre distributeur local Your local distributor: Hycultec GmbHHycultec
  • Activité biologique
  • Chemical Information
  • Solvant et solubilité
  • Pureté et documentation
  • Références
  • Help & FAQs
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) p38 MAPK-IN-1

More
Customer Validation & Images
WBFlow CytometryIn Vivo ImagingCell Imaging/StainingIn Vivo Efficacy StudyHistological Imaging/Staining
  • Flow Cytometry
  • WB
  • WB
  • In Vivo Imaging
  • In Vivo Efficacy Study
  • In Vivo Imaging
  • WB
  • Cell Imaging/Staining
  • In Vivo Efficacy Study
  • Histological Imaging/Staining

Voir tous les produits spécifiques à Isoform p38 MAPK

More
Keywords
MOQ
Minimum order quantity
100 mg

Obtenir un devis En stock

Other size
Obtenir un devis
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Enregistrer
Sign in to MedChemExpress
Enregistrer un nouveau compte

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • p38 MAPK-IN-1 Chemical Structure
    p38 MAPK-IN-1 Chemical Structure
    1/16
  • 1/16

    p38 MAPK-IN-1 purchased from MedChemExpress. Usage Cited in: Adv Biol (Weinh). 2025 Sep;9(9):e00761. [Abstract]

    Customer Validation
     Macrophages were pretreated with inhibitors of the ERK (HY‐112287; ERK1/2 inhibitor 1), JNK (HY‐12041; SP600125), p38 MAPK (HY‐12839; p38 MAPK-IN-1), and p65 NF‐kB (HY‐138537; NF-κB-IN-1) pathways prior to incubation with pyroptotic‐CM for 4 h.The MET formation by macrophages was evaluated with SYTOX Green staining and detected by flow cytometry.

  • 1/16

    p38 MAPK-IN-1 purchased from MedChemExpress. Usage Cited in: Adv Biol (Weinh). 2025 Sep;9(9):e00761. [Abstract]

    Customer Validation
     Macrophages were pretreated with inhibitors of the ERK (HY‐112287; ERK1/2 inhibitor 1), JNK (HY‐12041; SP600125), p38 MAPK (HY‐12839; p38 MAPK-IN-1), and p65 NF‐kB (HY‐138537; NF-κB-IN-1) pathways prior to incubation with pyroptotic‐CM for 4 h. The p‐p38 and p‐p65 levels in macrophages were measured by western blotting.

  • 1/16

    p38 MAPK-IN-1 purchased from MedChemExpress. Usage Cited in: Int J Biol Macromol. 2024 Nov;281(Pt 1):136178. [Abstract]

    Customer Validation
     S100A9 upregulated the expression of LCN2 in HK-2 cells via activating the TLR4-p38/MAPK signaling pathway. Supplementing p38 MAPK-IN-1 kept S100A9 from enhancing LCN2 expression in HK-2 cells.

  • 1/16

    p38 MAPK-IN-1 purchased from MedChemExpress. Usage Cited in: Int J Biol Macromol. 2024 Nov;281(Pt 1):136178. [Abstract]

    Customer Validation
     Paquinimod (HY-100442;ip; 15 mg/kg/d for seven days) and p38 MAPK-IN-1 (HY-12839; ip; 1 mg/kg/d for seven days ) both reduced the renal deposition of calcium in nephrocalcinosis mice.

  • 1/16

    p38 MAPK-IN-1 purchased from MedChemExpress. Usage Cited in: Int J Biol Macromol. 2024 Nov;281(Pt 1):136178. [Abstract]

    Customer Validation
     Paquinimod (HY-100442;ip; 15 mg/kg/d for seven days) and p38 MAPK-IN-1 (HY-12839; ip; 1 mg/kg/d for seven days ) both reduced the renal deposition of calcium in nephrocalcinosis mice.

  • 1/16

    p38 MAPK-IN-1 purchased from MedChemExpress. Usage Cited in: Int J Biol Macromol. 2024 Nov;281(Pt 1):136178. [Abstract]

    Customer Validation
     Paquinimod (HY-100442;ip; 15 mg/kg/d for seven days) and p38 MAPK-IN-1 (HY-12839; ip; 1 mg/kg/d for seven days ) both reduced the renal deposition of CaOx crystals in nephrocalcinosis mice.

  • 1/16

    p38 MAPK-IN-1 purchased from MedChemExpress. Usage Cited in: Cell Commun Signal. 2023 May 1;21(1):86. [Abstract]

    Customer Validation
     Neutrophils were pretreated with inhibitors of the ERK (HY-112287;ERK1/2 inhibitor 1), p38 MAPK (HY-12839; p38 MAPK-IN-1), and p65 NF-кB (HY-138537; NF-κB-IN-1) pathways prior to incubation with hypoxic-CM from GC cells. The protein levels of p-ERK, p-p38, and p-p65 in neutrophils were measured by western blotting.

  • 1/16

    p38 MAPK-IN-1 purchased from MedChemExpress. Usage Cited in: Cell Commun Signal. 2023 May 1;21(1):86. [Abstract]

    Customer Validation
     Neutrophils were pretreated with inhibitors of the ERK (HY-112287;ERK1/2 inhibitor 1), p38 MAPK (HY-12839; p38 MAPK-IN-1), and p65 NF-кB (HY-138537; NF-κB-IN-1) pathways prior to incubation with hypoxic-CM from GC cells. The NET formation by neutrophils was evaluated with MPO and citH3 staining. Magnification: 20 × . Scale bars: 50 μm.

  • 1/16

    p38 MAPK-IN-1 purchased from MedChemExpress. Usage Cited in: Cell Commun Signal. 2023 May 1;21(1):86. [Abstract]

    Customer Validation
     NETs accelerate tumour growth in vivo via angiogenesis. Subcutaneous AGS tumour growth was increased in the presence of NET-producing neutrophils from LPS-treated mice in vivo (n = 5 each group). LPS (10 μg/mouse) was intraperitoneally injected to induce systemic inflammation in BALB/c nude mice. Deoxyribonuclease I (DNase I, 100 U/mouse) or a p38 MAPK signalling pathway inhibitor (HY-12839; p38 MAPK-IN-1; 1 mg/kg) was injected intraperitoneally 24 h before injection of LPS as the NET inhibitor.

  • 1/16

    p38 MAPK-IN-1 purchased from MedChemExpress. Usage Cited in: Cell Commun Signal. 2023 May 1;21(1):86. [Abstract]

    Customer Validation
     NETs accelerate tumour growth in vivo via angiogenesis. LPS (10 μg/mouse) was intraperitoneally injected to induce systemic inflammation in BALB/c nude mice. Deoxyribonuclease I (DNase I, 100 U/mouse) or a p38 MAPK signalling pathway inhibitor (HY-12839; p38 MAPK-IN-1; 1 mg/kg) was injected intraperitoneally 24 h before injection of LPS as the NET inhibitor. Increased angiogenesis in tumours of LPS-treated mice compared to control mice. Representative images of CD31 staining are shown. Magnification: 20 × . Scale bars: 50 μm. All values are the means ± SDs. *P < 0.05, **P < 0.01.

  • p38 MAPK-IN-1